This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamashita, Y.-i. Articles by Sugimachi, K. Search for Related Content PubMed PubMed Citation Articles by Yamashita, Y.-i. Articles by Sugimachi, K.

Electroporation-mediated Interleukin-12 Gene Therapy for Hepatocellular Carcinoma in the Mice Model

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582 [Y-i. Y., M. S., H. H., T. R., T. H., S. T., K. Sh., K. Su.]; Department of Immunology, Medical Institute of Bioregulation, Fukuoka 812-8582 [R. M.]; and Department of Nutrition and Physiological Chemistry, Osaka University Medical School, Osaka 565-0871 [J-i. M.], Japan

Applications of nonviral vectors for gene transfer into tumors in vivo have been limited by the relatively low expression levels of the transferred gene. The aim of this study is to evaluate the efficacy of electroporation-mediated interleukin-12(IL-12) gene therapy for hepatocellular carcinoma (HCC). First, we investigated the optimal conditions of electric pulses (voltage, pulsing duration, numbers of shocks) of in vivo electroporation for gene transfer into HCC established by s.c. implantation of MH134 cells to C3H mice. This process made use of plasmid DNA that express the luciferase gene. We concluded that the optimal conditions for the electric pulses are as follows: voltage at 150 V; pulsing duration at 50 ms; nonpulsing duration at 950 ms; and the number of shocks at 10. Second, we tried to treat s.c. HCC by electroporation using plasmid DNA that expresses the murine interleukin-12 (mIL-12) gene. Intratumoral administration of the mIL-12 vector elevated serum IL-12 and IFN- and significantly inhibited the growth not only of HCC into which the mIL-12 vector had been directly transferred, but also of the distant HCC. In addition, intratumoral administration of the mIL-12 vector inhibited spontaneous lung metastasis and delayed establishment of HCC injected 3 days after mIL-12 gene therapy. The IL-12 gene therapy induced more lymphocyte infiltration by NK cells, CD3⁺ cells, and Mac-1 positive cells into the tumor and reduced the number of microvessels. Therefore, more terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive tumor cells were found. These results demonstrate that gene therapy for HCC by electroporation in vivo using IL-12 is very efficient and is thus promising for further clinical trial.

This article has been cited by other articles:

				A. I. Daud, R. C. DeConti, S. Andrews, P. Urbas, A. I. Riker, V. K. Sondak, P. N. Munster, D. M. Sullivan, K. E. Ugen, J. L. Messina, et al. Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma J. Clin. Oncol., December 20, 2008; 26(36): 5896 - 5903. [Abstract] [Full Text] [PDF]

				Y. Takei, T. Nemoto, P. Mu, T. Fujishima, T. Ishimoto, Y. Hayakawa, Y. Yuzawa, S. Matsuo, T. Muramatsu, and K. Kadomatsu In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency Mol. Cancer Ther., January 1, 2008; 7(1): 211 - 221. [Abstract] [Full Text] [PDF]

				W. Kim, J.-H. Yoon, J.-M. Jeong, G.-J. Cheon, T.-S. Lee, J.-I. Yang, S.-C. Park, and H.-S. Lee Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma Mol. Cancer Ther., September 1, 2007; 6(9): 2554 - 2562. [Abstract] [Full Text] [PDF]

				H. Matsubara, Y. Mizutani, F. Hongo, H. Nakanishi, Y. Kimura, S. Ushijima, A. Kawauchi, T. Tamura, T. Sakata, and T. Miki Gene therapy with TRAIL against renal cell carcinoma. Mol. Cancer Ther., September 1, 2006; 5(9): 2165 - 2171. [Abstract] [Full Text] [PDF]

				M. N. Torrero, W. G. Henk, and S. Li Regression of High-Grade Malignancy in Mice by Bleomycin and Interleukin-12 Electrochemogenetherapy Clin. Cancer Res., January 1, 2006; 12(1): 257 - 263. [Abstract] [Full Text] [PDF]

				T. Yamaoka, Y. Yonemitsu, K. Komori, H. Baba, T. Matsumoto, T. Onohara, and Y. Maehara Ex vivo electroporation as a potent new strategy for nonviral gene transfer into autologous vein grafts Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1865 - H1872. [Abstract] [Full Text] [PDF]

				N. Harada, M. Shimada, S. Okano, T. Suehiro, Y. Soejima, Y. Tomita, and Y. Maehara IL-12 Gene Therapy Is an Effective Therapeutic Strategy for Hepatocellular Carcinoma in Immunosuppressed Mice J. Immunol., December 1, 2004; 173(11): 6635 - 6644. [Abstract] [Full Text] [PDF]

				C.-J. Chang, K.-F. Tai, S. Roffler, and L.-H. Hwang The Immunization Site of Cytokine-Secreting Tumor Cell Vaccines Influences the Trafficking of Tumor-Specific T Lymphocytes and Antitumor Efficacy against Regional Tumors J. Immunol., November 15, 2004; 173(10): 6025 - 6032. [Abstract] [Full Text] [PDF]

				Y.-i. Yamashita, M. Shimada, R. Minagawa, E. Tsujita, N. Harimoto, S. Tanaka, K. Shirabe, J.-i. Miyazaki, and Y. Maehara Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation Mol. Cancer Ther., September 1, 2004; 3(9): 1177 - 1182. [Abstract] [Full Text] [PDF]

				F Xue, T Takahara, Y Yata, Y Kuwabara, E Shinno, K Nonome, M Minemura, S Takahara, X Li, E Yamato, et al. Hepatocyte growth factor gene therapy accelerates regeneration in cirrhotic mouse livers after hepatectomy Gut, May 1, 2003; 52(5): 694 - 700. [Abstract] [Full Text]

				J. Jiang, E. Yamato, and J.-i. Miyazaki Sustained Expression of Fc-Fusion Cytokine Following In Vivo Electroporation and Mouse Strain Differences in Expression Levels J. Biochem., April 1, 2003; 133(4): 423 - 427. [Abstract] [Full Text] [PDF]

				S. Li, X. Zhang, and X. Xia Regression of Tumor Growth and Induction of Long-Term Antitumor Memory by Interleukin 12 Electro-Gene Therapy J Natl Cancer Inst, May 15, 2002; 94(10): 762 - 768. [Abstract] [Full Text] [PDF]

				K. Mikata, H. Uemura, H. Ohuchi, S. Ohta, Y. Nagashima, and Y. Kubota Inhibition of Growth of Human Prostate Cancer Xenograft by Transfection of p53 Gene: Gene Transfer by Electroporation Mol. Cancer Ther., February 1, 2002; 1(4): 247 - 252. [Abstract] [Full Text] [PDF]